Fabricatore, Anthony N.

Evidence for prospective associations among depression and obesity in population‐based studies

Faith, M. S., Butryn, M., Wadden, T. A., Fabricatore, A., Nguyen, A. M., & Heymsfield, S. B. (2011) · Obesity Reviews

Eating Disorders and BehaviorsObesity, Physical Activity, Diet

Cited by 340

One‐Year Changes in Symptoms of Depression and Weight in Overweight/Obese Individuals With Type 2 Diabetes in the Look AHEAD Study

Faulconbridge, L. F., Wadden, T. A., Rubin, R. R., Wing, R. R., Walkup, M. P., Fabricatore, A. N., Coday, M., Van Dorsten, B., Mount, D. L., Ewing, L. J., et al. (2012) · Obesity

Diabetes Management and EducationDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 117

Changes in neural responsivity to highly palatable foods following roux‐en‐Y gastric bypass, sleeve gastrectomy, or weight stability: An f MRI study

Faulconbridge, L. F., Ruparel, K., Loughead, J., Allison, K. C., Hesson, L. A., Fabricatore, A. N., Rochette, A., Ritter, S., Hopson, R. D., Sarwer, D. B., et al. (2016) · Obesity

Bariatric Surgery and OutcomesRegulation of Appetite and Obesity

Cited by 78

Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real‐world setting: A 6‐month retrospective study in the United States (SCOPE)

Ruseva, A., Michalak, W., Zhao, Z., Fabricatore, A., Hartaigh, B. Ó., & Umashanker, D. (2024) · Obesity Science & Practice

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 40

Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

Nanna, M. G., Doan, Q. V., Fabricatore, A., Faurby, M., Henry, A. D., Houshmand‐Oeregaard, A., Levine, A., Navar, A. M., Scassellati Sforzolini, T., & Toliver, J. C. (2025) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 10